Overview
PHVS market data
Price History
PHVS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.97 Diluted earnings per share over the trailing twelve months.
- Beta
- -2.65 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $20.65 – $36.93 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.4B · P/B 5.68.
Company News
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52Benzinga · Aug 13, 2026, 3:37 PM
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40Benzinga · Aug 13, 2026, 2:19 PM
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75Benzinga · Aug 13, 2026, 1:50 PM
Pharvaris Q2 EPS $(0.81) Misses $(0.74) EstimateBenzinga · Aug 12, 2026, 10:53 AM
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in ImmunologyGlobenewswire Inc · Aug 6, 2026, 11:15 AM
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?The Motley Fool · Jul 24, 2026, 12:15 PM
Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & ImmunologyBenzinga · Jul 22, 2026, 10:53 AM
Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55Benzinga · Jul 15, 2026, 11:03 AM
Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027Benzinga · Jul 6, 2026, 11:00 AM
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46Benzinga · Jun 25, 2026, 5:40 PM